Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Goodwill & Intangibles: 2014-2025

Historic Goodwill & Intangibles for Aytu Biopharma (AYTU) over the last 12 years, with Jun 2025 value amounting to $55.4 million.

  • Aytu Biopharma's Goodwill & Intangibles fell 22.48% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year decrease of 22.48%. This contributed to the annual value of $55.4 million for FY2025, which is 22.48% down from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Goodwill & Intangibles is $55.4 million, which was down 22.48% from $71.5 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Goodwill & Intangibles registered a high of $160.0 million during FY2021, and its lowest value of $55.4 million during FY2025.
  • In the last 3 years, Aytu Biopharma's Goodwill & Intangibles had a median value of $71.5 million in 2024 and averaged $68.5 million.
  • In the last 5 years, Aytu Biopharma's Goodwill & Intangibles skyrocketed by 107.97% in 2021 and then tumbled by 41.12% in 2022.
  • Yearly analysis of 5 years shows Aytu Biopharma's Goodwill & Intangibles stood at $160.0 million in 2021, then crashed by 41.12% to $94.2 million in 2022, then dropped by 16.60% to $78.6 million in 2023, then dropped by 9.05% to $71.5 million in 2024, then decreased by 22.48% to $55.4 million in 2025.